H.C. Wainwright downgraded 89bio (ETNB) to Neutral from Buy with a price target of $14.50, down from $32, after the company entered into a merger agreement to be acquired by Roche (RHHBY) for $14.50 per share in cash.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETNB: